Cationic oligonucleotides, automated methods for preparing same and their uses

ABSTRACT

The invention relates to oligonucleotide-oligocation molecules A i B j H that can be synthetized via automated phosphoramidite chemistry having oligonucleotides moieties Ai and oligocations moieties Bj, wherein •A i  is an i-mer oligonucleotide residue, with i=5 to 50, where nucleotide A is an oligomer with naturally or non naturally occurring nucleobases and/or pentafuranosyl groups and/or native phosphodiester bonds, for example selected from the group comprising deoxyribo, ribo, locked (LNA) nucleotides as well as their chemical modifications or substitutions such as phosphorothioate, 2′-fluoro, 2′-O-alkyl, or a marker group such as a fluorescent agent, •Bj is a j-mer organic oligocation moiety, with j=1 to 50, where B is selected from the group comprising •—HPO 3 —R 1 —(X—R 2   n ) n1 —X—R 3 —O—, where R 1 , R 2 n and R 3 , identical or different, are lower alkylene, X is NH or NC(NH 2 ) 2 , n varies from 1 to 5 and n1=2 to 20, •—HPO 3 —R 4 —CH(R 5 X 1 )—R 6 —O—, where R 4  is lower alkylene, R 5  and R 6 , identical or different, are lower alkylene and X 1  is putrescine, spermidine or spermine residue, •—HPO 3 —R 7 -(aa) n2 -R 8 —O—, where R 7  is lower alkylene and R 8  is lower alkylene, serine, a natural aminoalcohol, (aa) n2  is a peptide containing natural aminoacids with cationic side chains, such as Arginine, Lysine, Ornithine, -Histidine, Diaminopropionic acid and n2=2 to 20.

This application is the U.S. national phase of International ApplicationNo. PCT/IB2006/004085, filed 14 Dec. 2006, which designated the U.S. andclaims the benefit of U.S. Provisional Application No. 60/750,346, filed15 Dec. 2005, the entire contents of each of which are herebyincorporated by reference.

The invention relates to cationic oligonucleotides, i.e,oligonucleotide-oligocation molecules, also called cationicoligonucleotides in the description (irrespective of their globalcharge) that can be synthetized stepwise on an oligonucleotidesynthetizer. It also pertains to their use, in molecular biology,diagnostics and therapeutic applications.

Oligonucleotides find an extremely large number of applications inmolecular biology and diagnostics, and may become a very selective classof drugs for the treatment of a vast palette of diseases.

Oligonucleotides are polyanions that exert their specific activityfollowing hybridization to a complementary sequence borne by anotherpolyanionic nucleic acid.

As drug candidates, they must also be capable of crossing the anioniccell membrane.

Simple electrostatic considerations imply that hybridization energy andcell binding could benefit from the addition of cationic groups to theoligonucleotide structure.

Towards this goal, many synthetic approaches for introducing ammonium orguanidinium residues into oligonucleotides have been explored: phosphatebackbone replacement, ribose or nucleic base modification, and endconjugation of a polycation. However, hybridization specificity, nucleicacid-processing enzyme activity as well as metabolite toxicity concernsall point to the block approach, where the polycation is appended to anotherwise natural oligonucleotide, as the best solution. Unfortunately,stepwise automated synthesis of oligonucleotide-cationic peptideconjugates is not yet routine. On the other hand, conjugation chemistrybetween preformed large blocks is not straightforward, especially inwater, where <<super>>zwitterions raise intractable solubility,purification and characterization problems. Moreover, molecular biologyand diagnostics applications require fast and straightforward synthesisof any given base sequence linked to any organic cation length.

The inventors have found that an online, computer driven, synthesis ofoligonucleotide-oligocation molecules was possible by plugging vialscontaining properly activated and protected oligocationic derivatives toan oligonucleotide synthetizer in addition to those of the four naturalbases.

An object of the invention is thus to provide new cationicoligonucleotides.

Another object of the invention is to provide a high yield, automatedsynthesis of said cationic oligonucleotides.

In a further object, the invention relates to the applications of saidcationic oligonucleotides, particularly in molecular biology,diagnostics and therapeutics.

The invention thus relates to mixed oligonucleotide oligocationmolecules that can be synthetized via automated phosphoramiditechemistry, i.e., polyphosphodiesters.

More particularly, the cationic oligonucleotides A_(i)B_(j)H of theinvention have oligonucleotides moieties Ai and oligocations moietiesBj, wherein

A_(i) is an i-mer oligonucleotide residue, with i=5 to 50 with naturallyor non naturally occurring nucleobases and/or pentafuranosyl groupsand/or native phosphodiester bonds,

Bj is a j-mer organic oligocation moiety, with j=1 to 50, where B isselected from the group comprising

-   -   —H—PO₃R¹—(X—R²)_(n1)—X—R³—O—, wherein R¹, R² and R³, identical        or different, are lower alkylene, X is NH or NC(NH₂)₂, and n1=2        to 20,    -   —HPO₃—R⁴—CH(R⁵X¹)—R⁶—O—, where R⁴ is lower alkylene, R⁵ and R⁶,        identical or different, are lower alkylene and X¹ is putrescine,        spermidine or spermine residue,    -   —H—PO₃—R⁷-(aa)_(n2)-R⁸—O—, where R⁷ is lower alkylene and R⁸ is        lower alkylene, serine, an aminoalcohol, (aa)_(n2) is a peptide        containing natural aminoacids with cationic side chains, such as        Arginine, Lysine, Ornithine, Histidine, Diaminopropionic acid        and n2=2 to 20.)

“Lower alkyl” and “lower alkylene”, as used in the description and theclaims, preferably designate an optionally substituted C1-C5 linear orbranched alkyl or alkylene radical, respectively.

A is for example selected from the group comprising deoxyribo, ribo,locked (LNA) nucleotides as well as their chemical modifications orsubstitutions such as phosphorothioate (also designated thiophosphate),2′-fluoro, 2′-O-alkyl or a marker group such as a fluorescent agent.

Mixed oligonucleotide-oligocation molecules of the invention have^(3′)A^(5′)-B sequence.

Other molecules of the invention have B-^(3′)A⁵ sequence.

Still other molecules of the invention have B-^(3′)A^(5′)-B or^(3′)A^(5′)-B-^(3′)A^(5′) sequence.

Such a sequence is illustrated in the examples by anoligonucleotide-spermine molecule having the following structure:

wherein A, i and j are as above defined.

Molecules with A being a phosphorothioate nucleotide are particularlyadvantageous in view of their biological applications, sincephosphorothioate oligonucleotides are not hydrolyzed in biologicalfluids.

The above defined cationic oligonucleotides form fast and stablecomplexes with their complementary sequence in a strand replacementcontext and even in a plasmid strand invasion context, as illustrated bythe examples.

Due to end conjugation, sequence selectivity remains as high as fornatural nucleotides.

Accordingly, the cationic oligonucleotides of the invention are of greatinterest for molecular biology, research reagents and diagnosticsapplications, such as PCR, real-time PCR, genotyping, in situhybridization and DNA chips.

Such applications are then also covered by the invention and comprisethe use of oligonucleotide-oligocation molecules such as above defined.

In contrast to anionic oligonucleotides, cationic oligonucleotides ofthe invention are shown in the examples to spontaneously enter thecytoplasm and nucleus of living cells.

In view of their enhanced hybridization and cell permeation properties,they are also useful for therapeutic approaches, such as those mediatedby antisense and siRNA degradation of messenger RNA, by exon skippingduring messenger RNA maturation, by triple helix formation withchromatin, by chromatin strand invasion (gene correction) . . . .

The invention thus also relates to pharmaceutical compositionscomprising an effective amount of oligonucleotide-oligocation moleculessuch as above defined, in association with a pharmaceutically acceptablecarrier.

The invention also relates to a method of treatment comprising using aneffective amount of oligonucleotide-oligocation molecules such as abovedefined, in association with a pharmaceutically acceptable carrier.

The above defined mixed oligonucleotide-oligocation molecules areadvantageously stepwise synthetized on an oligonucleotide synthetizer,via the phosphoramidite route, according to a method comprising

plugging vials containing activated and protected oligocations B to anoligonucleotide synthetizer, in addition to vials of oligonucleotides Asuch as above defined, or the reverse,

stopping the synthesis, when the desired length is obtained,

cleaving the oligomers from the solid support, and

removing the protecting groups.

The invention is closely related to the phosphoramidite reagents used inthe automated synthesis for the construction of oligocation repeatedblock B. The following phosphoramidite reagents can be used for thispurpose

-   -   P(OR⁹)(N(R¹⁰)₂)—O—R¹—(X—R²—X—R³—O-Prot where R¹, R², R³, and n1        are as above defined, X is suitably protected NH or NC(NH₂)₂, R⁹        is —CH₂CH₂CN, or lower alkyl, R¹⁰ is lower alkyl, or —N(R¹⁰)₂ is        pyrrolidino, piperidino or morpholino group, and Prot is a        protecting group used in oligonucleotide synthesis, such as DMT,        MMT;    -   P(OR⁹)(N(R¹⁰)₂)—O—R⁴—CH(R⁵X1)-R⁶—O-Prot, where R⁴, R⁵, R⁶ are        lower alkylene, X¹ is suitably protected putrescine, spermidine        or spermine, R⁹ and R¹⁰ are as above defined;    -   P(OR⁹)(N(R¹⁰)₂)—O—R⁷-(aa)_(n2)-R⁸—O-Prot, where R⁷, R⁸, R⁹, R¹⁰,        n2, and Prot are as above defined, (aa)_(n2) is a peptide        containing natural aminoacids with suitably protected cationic        side chains, such as Arginine, Lysine, Ornithine, Histidine,        Diaminopropionic acid and n2=2 to 20.

Suitably protected NH or NC(NH₂)₂ means that protecting groups arepresent on the amino or guanidine residue, respectively, to render theirfunctionality inert to chemical reaction conditions to which the reagentis exposed.

Such protecting group are for example phthalimide (PHTH),trifluoroacetate, allyloxycarbonyl (Alloc), benzyloxycarbonyl (CBZ),chlorobenzyloxycarbonyl, t-butyloxycarbonyl (Boc),fluorenylmethoxycarbonyl (Fmoc) and isonicotinyloxy (i-Noc) groups.

According to an embodiment of the invention, stepwise synthesis of theoligonucleotide sequence is followed by stepwise synthesis of theoligocation moiety to obtain compounds having sequence (^(3′)A^(5′)-B).

According to another embodiment, reverse steps are performed, thestepwise synthesis of oligocation moiety being followed by stepwisesynthesis of the oligonucleotide sequence to obtain compounds of(B-^(3′)A^(5′)) sequence.

According to still another embodiment, mixed sequences are synthetized.

In particular, oligonucleotide sequences capped at both ends(B-^(3′)A5′-B) can resist exonucleases in biological fluids, andcation-interrupted sequences (^(3′)A^(5′)-B-^(3′)A^(5′)) allow targetingof vicinal nucleic acid sequences.

By using naturally occurring amines like spermine, or peptides such asoligoarginines, potential toxicity of metabolites is avoided. Spermineis indeed present at millimolar concentration in cells and itsend-alkylation is harmless. Moreover, basic peptide sequences arepresent in many nuclear proteins.

The activated and protected oligocations B are advantageously obtainedby protecting the amino groups of a polyamine, followed by α,ω-bishydroxylalkylation, leading to diols compatible with oligonucleotidesynthesis.

Classical DMT and phosphoramidite elongation chemistry is advantageouslyimplemented together with base-labile TFA protecting groups.

The chemically protected diols are new products and enter into the scopeof the invention.

The invention particularly relates to the intermediates selected fromthe group comprising

-   -   P(OR⁹)(N(R¹⁰)₂)—O—R¹—(X—R²)—X—R³—O-Prot where R¹, R², R³, and n1        are as above defined, X is suitably protected NH or NC(NH₂)₂, R⁹        is —CH₂CH₂CN, or lower alkyl, R¹⁰ is lower alkyl, or —N(R¹⁰)₂ is        pyrrolidino, piperidino or morpholino group, and Prot is a        protecting group used in oligonucleotide synthesis, such as DMT,        MMT;    -   P(OR⁹)(N(R¹⁰)₂)—O—R⁴—CH(R⁵—X1)-R⁶—O-Prot, where R⁴, R⁵, R⁶ are        lower alkylene, X¹ is suitably protected putrescine, spermidine        or spermine, R⁹ and R¹⁰ are as above defined;    -   P(OR⁹)(N(R¹⁰)₂)—O—R⁷-(aa)_(n2)-R⁸—O-Prot, where R⁷, R⁸, R⁹, R¹⁰,        n2, and Prot are as above defined, (aa)_(n2) is a peptide        containing natural aminoacids with suitably protected cationic        side chains, such as Arginine, Lysine, Ornithine, Histidine,        Diaminopropionic acid and n2=2 to 20.

Other characteristics and advantages of the invention are givenhereinafter. In particular, the synthesis of decamer oligonucleotidicsequences (A₁₀) with spermine (S), designated by A₁₀S_(n) in thefollowing will be given by way of illustration, without limiting theinvention. In the examples, it will be referred to FIGS. 1 to 14, whichrepresent, respectively:

FIG. 1, HPLC analysis of cationic oligonucleotides N₁₀S_(n) (n=1-2) on areverse-phase column,

FIG. 2, HPLC analysis of purified oligonucleotides N₁₀S_(n) (n=1-6) onan anion exchange column,

FIG. 3, analysis of N₁₀S_(n) (n=1-6) electrophoretic mobility bypolyacrylamide gel electrophoresis,

FIG. 4, spontaneous exchange of N₁₀ with N₁₀.C₁₀ at varioustemperatures,

FIG. 5, strand exchange between N₁₀ and N₁₀S_(n) as revealed bypolyamide gel electrophoresis

FIG. 6, melting temperatures of N₁₀S_(n).C₁₀ duplexes (where C is thenucleotide complementary to N),

FIG. 7: comparative results of melting temperatures of duplexes formedby N₁₀S_(n) (n=0-6) with ^(5′)GTGGCATCGC^(3′) (SEQ ID NO:1) and with^(5′)GTGGCGTCGC^(3′) (SEQ ID NO:2)

FIG. 8, ES-MS analysis of purified N₁₀S_(n) (n=1-6) oligonucleotides,

FIG. 9, HPLC traces of phosphorothioate oligonucleotides N₁₂S₁₁F (9A)and N₁₂S₂F (9B),

FIG. 10, MALDI-TOF MS spectra of N₁₂S₂F (10 A) and N₁₂S₁₁F (10 B),

FIG. 11, HPLC traces of N₁₄S₄F (Bottom) and N₂₀S₅F (Top, respectively,

FIG. 12, MALDI-TOF MS spectra of N₁₄S₄F (12A) and N₂₀S₅F (12B),

FIG. 13, strand invasion of pGL2 and pGL3 plasmids by N₁₄S_(n)F (13A)and N₂₀S_(n)F (13B).

FIGS. 14A and 14B, penetration of the cationic oligonucleotide F—S₁₈N₁₉into HeLa cells.

EXAMPLE 1 Synthesis of Phosphoramidite Spermine Synthon

The spermine tethered phosphoramidite 1 was synthesized from spermine asshown in following Scheme 1:

(Mes=2,4,6-trimethylphenyl; TBDMS=t-butyldimethylsilyl; TFA=CF₃CO—;DMT=4,4′-dimethoxytrityl)

Tetrakis(mesitylsulfonyl)spermine 2, prepared from spermine, wasbis-alkylated to 3. After complete deprotection of 3 in acidicconditions, the crude bis(C4-OH)spermine tetrahydrobromide 4 was fullyprotected by trifluoroacetic anhydride in pyridine, then the twoterminal ester group of 5 were hydrolyzed in neutral conditions to diol6. Mono tritylation of 5 was performed in statistical way using onemolar equivalent of DMTCl reagent to afford 7 in 43% yield. Unreacteddiol 6 and bis-trityl compound 8 were recovered and re-equilibrated inmild acidic conditions (trifluoroacetic acid in dichloromethane) toafford 7. Phosphitylation of 7 gave the desired phosphoramidite 1.

N¹,N⁴,N⁹,N¹²-Tetrakis(mesitylsulfonyl)spermine (2): This compound wasprepared according to the reference: Bergeron et al. J. Med. Chem. 2001,44, 232-244.

N¹,N¹²-Bis[4-(t-butyldimethylsilyloxy)butyl]-N¹,N⁴,N⁹,N¹²-tetrakis(mesitylsulfonyl)-spermine(3): Sodium hydride (60%, 1.0 g, 25 mmol) was added in portions withstirring under N₂ at 0° C. to a solution of 2 (9.31 g, 10.0 mmol) in DMF(20 mL). After stirring at room temperature for 30 min,t-butyl(4-iodobutoxy)dimethylsilane (7.86 g, 25 mmol) was added in oneportion. The mixture was stirred overnight at room temperature and thenpartitioned between H₂O—CH₂Cl₂ (100 mL/100 mL). Organic phase wasseparated and the aqueous phase was extracted three times with CH₂Cl₂(50 mL). Combined organic phases were washed with NaHCO₃ (1 M) solutionand then dried on MgSO₄. After evaporation, pasty residue was purifiedby flash chromatography with 1:4 AcOEt:cyclohexane as eluant. Thefractions containing 3 were evaporated to a pasty oil which was furtherwashed with cold pentane to eliminate fast moving impurity and thenpumped in vacuo to afford 9.97 g (76%) of 3 as an oil: TLC(AcOEt/cyclohexane 1:4): R_(f)=0.28. IR (KRS-5): 2937, 1604, 1471, 1320,1151, 1101, 838, 777, 657, 578 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ=−0.01(s, 12H), 0.85 (s, 18H), 1.20-1.45 (m, 12H), 1.62 (m, 4H), 2.28 (s, 6H),2.29 (s, 6H), 2.53 (s, 12H), 2.54 (s, 12H), 2.90-3.10 (m, 16H), 3.42 (t,J=6.1 Hz, 4H), 6.91 (s, 4H), 6.92 (s, 4H). ¹³C NMR (75 MHz, CDCl₃):δ=4.7, 18.9, 21.6, 23.4, 23.5, 24.1, 24.9, 25.7, 26.6, 30.4, 43.5, 43.6,45.6, 45.7, 62.9, 132.59, 132.64, 133.8, 140.7, 143.0, 143.1. MS-ESI(MeOH): m/z=1325.85 [M+Na]⁺, 1303.83 [M+H]⁺. C₆₆H₁₁₀N₄O₁₀S₄Si₂(Mw=1304.03) calcd. C, 60.79; H, 8.50; N, 4.30; S, 9.84. found: C,60.74; H, 8.55; N, 4.21; S, 9.63.

N¹,N¹²-Bis(4-hydroxybutyl)spermine tetrahydrobromide (4): Hydrogenbromide in acetic acid (33% wt solution, 80 mL, 1.4 mol) was addeddropwise to a solution of 3 (9.87 g, 7.57 mmol) and phenol (29.0 g, 0.31mol, 40 equiv.) in CH₂Cl₂ (80 mL). The reaction mixture was stirredovernight at room temperature. On cooling with an ice bath, cold water(100 mL) was added with stirring. Organic layer was separated andextracted three times with water (20 mL). Combined aqueous layers werewashed five times with CH₂Cl₂ (30 mL) and evaporated to dryness.Resulting humid solid residue was suspended in ether, triturated withspatula and the supernatant ether layer was discarded. These operationswere repeated (five times) until a solid suspension was obtained. Afterevaporation and drying in vacuo, compound 4 was obtained as a solid(5.32 g). This crude materiel was used without further purification: ¹HNMR (300 MHz, D₂O): δ=1.75-2.10 (m, 12H), 2.27 (m, 4H), 3.15-3.35 (m,16H), 3.76 (t, J=12.2 Hz, 4H). ¹³C NMR (75 MHz, D₂O): δ=22.9, 23.2,23.4, 29.0, 45.0, 45.2, 47.7, 48.3, 61.5. MS-ESI (MeOH): m/z=347.39[M+H]⁺.

N¹,N¹²-Bis(4-(trifluoroacetoxy)butyl)-N¹,N⁴,N⁹,N¹²-tetrakis(trifluoroacetyl)spermine (5) (from 4 with TFA₂O/NEt₃): To a suspension of 4 (5.3 g, 7.6mmol) in CH₂Cl₂ (50 mL), triethylamine (11.5 g, 114 mmol, 15 equiv.) wasadded in one portion. The mixture was cooled on an ice-bath andtrifluoroacetic anhydride (19.1 g, 90. 9 mmol: 12 equiv.) was addeddropwise with stirring under N₂. The mixture was stirred at roomtemperature for 3.5 h. After cooling on an ice-bath, the resultingsolution was washed three times with cold water (20 mL), dried on MgSO₄and then evaporated to afford an oily residue (11.7 g) which contains assecondary product of this reaction, (TFA)₂C═CH-NEt₂ (ref Schreber, S.L., Tetrahedron Lett. 1980, 21, 1027). This was eliminated by twosuccessive flash chromatography (eluant 1:1-60:40 AcOEt:cyclohexane andthen 5-10% Et₂O/CH₂Cl₂) to afford 5 (5.59 g, 81%) as an oil: TLC(AcOEt/cyclohexane 1:1): R_(f)=0.25. IR (KRS-5): 2955, 1789, 1690, 1467,1352, 1197, 1147, 759, 731, 692 cm⁻¹. ¹H NMR (300 MHz, CDCl₃):δ=1.52-2.06 (m, 16H), 3.33-3.49 (m, 16H), 3.38 (m, 4H). ¹³C NMR (75 MHz,CDCl₃): This spectrum is complicated by rotational isomerism of fouramide groups. Only high intensity resonance signals are described asfollowing: δ=23.3, 23.9, 24.1, 24.8, 25.3, 25.6, 26.0, 26.55, 26.61,44.4, 44.8, 45.7, 46.1, 46.4, 47.3, 48.0, 56.6, 67.3, 67.5, 116.6 (q,J=288 Hz), 156.9, 157.4, 157.8, 158.6.

N¹,N¹²-Bis(4-hydroxybutyl)-N¹,N⁴,N⁹,N¹²-tetrakis(trifluoroacetyl)spermine(6): To a solution of 5 (5.39 g, 5.84 mmol) in MeOH (50 mL), NaHCO₃ (0.1g, solid) was added in one portion and the resulting suspension wasstirred for 2 h at room temperature. After evaporation, oil residue wasdissolved in CH₂Cl₂ (affording a suspension of some fibrous NaHCO₃) andpurified by flash chromatography eluting with 5-10% MeOH/CH₂Cl₂ toafford 3.61 g (85%) of 6 as an oil: TLC (MeOH 5%/CH₂Cl₂): R_(f)=0.14.(MeOH 10%/CH₂Cl₂): R_(f)=0.45. ¹H NMR (300 MHz, CDCl₃): δ=1.51-2.02 (m,18H), 3.33-3.51 (m, 16H), 3.68 (m, 4H). MS-ESI (MeOH): m/z=753.33[M+Na]⁺. C₂₆H₃₈F₁₂N₄O₆.H₂O (Mw=748.60) calcd. C, 41.72; H, 5.39; N,7.48; F, 30.45. found C, 41.97; H, 5.26; N, 7.37; F, 30.14.

Preparation of 6 from 4 (with TFA₂O/pyridine, then NaHCO₃): To asuspension of 4 (15.3 g, 22.8 mmol) in CH₂Cl₂ (100 mL) and pyridine (44mL, 0.54 mol), trifluoroacetic anhydride (46 mL, 0.33 mol) was addeddropwise with cooling on an ice bath and with stirring under N₂. Themixture was stirred at room temperature for 3 h. The excess oftrifluoroacetic anhydride was decomposed by addition of cold water (100mL) with cooling on an ice bath, then the resulting solution wasextracted with CH₂Cl₂ (four times 100 mL+50 mL+25 mL×2). The combinedextracts were washed with cold water (50 mL×3), dried on-MgSO₄ and thenevaporated to afford crude 5 (19.4 g, 92%) as oil. This oil wasdissolved in MeOH (100 mL). NaHCO₃ (solid, 0.1 g) was added and thesuspension was stirred overnight. After evaporation of solvent, theresidue was purified by flash chromatography with 5-7% MeOH:CH₂Cl₂ aseluant to afford 10.1 g (61%) of 6 as an oil.

N¹-[4-(Dimethoxytrityloxy)butyl]-N¹²-(4-hydroxybutyl)-N¹,N⁴,N⁹,N¹²-tetrakis(trifluoro-acetyl)spermine(7): To a solution of 6 (1.46 g, 2.00 mmol) in pyridine (3 mL), DMTCl(757 mg, 2.23 mmol) was added using 1 mL of pyridine to rinse. Thereaction mixture was stirred for 4 h at room temperature under N₂ andthen pyridine was repeatedly removed by coevaporation with toluene.Residue was purified by two successive flash chromatography (eluant 2-5%MeOH/CH₂Cl₂ and then 10-15% acetone/CH₂Cl₂) to afford 7 (879 mg, 43%) asfoam and bis-DMT derivative 8 (648 mg, 24%). Starting diol 6 was alsorecovered (350 mg, 24%). Data of 7: TLC (acetone/CH₂Cl₂ 1:9):R_(f)=0.20. ¹H NMR (300 MHz, CDCl₃): δ=1.51-2.03 (m, 17H), 3.11 (m, 2H),3.32-3.51 (m, 16H), 3.71 (m, 2H), 3.81 (s, 6H), 6.84 (m, 4H), 7.19-7.46(m, 9H). MS-ESI (MeOH): m/z=1055.52 [M+Na]⁺. C₄₇H₅₆F₁₂N₄O₈ (Mw=1032.95)calcd. C, 54.65; H, 5.46; N, 5.42; F, 22.07. found: C, 54.46; H, 5.58;N, 5.37; F, 21.63.

Compound (7) from diol (6) and bis-DMT derivative (8); To a solution of6 (1.4 g, 1.9 mmol) and 8 (2.59, 1.9 mmol) in CH₂Cl₂, trifluoroaceticacid (50 μL, 0.6 mmol) was added and stirred at room temperature for 30min. The solution was washed three times with Na₂CO₃ 1 M solution, driedon MgSO₄ and evaporated. Residue was separated by flash chromatography(column diameter: 50 mm, SiO₂ height: 15 cm) using successively 5%AcOEt/CH₂Cl₂ (750 mL), 33% AcOEt/CH₂Cl₂ (500 mL), 7% MeOH/CH₂Cl₂ (500mL) and 10% MeOH/CH₂Cl₂ (500 mL) to afford 8 (1.1 g), 7 (1.2 g) and 6(1.3 g).

Spermine tethered phosphoramidite (1): To a solution of 7 (844 mg, 817μmol) and triethylamine (230 μL, 1.65 mmol, 2 equiv.) in CH₂Cl₂ (4 mL),2-cyanoethyl-(N,N-diisopropylamino)chlorophosphite (205 μL, 0.92 mmol,1.1 equiv.) was added and the mixture was stirred under N₂ at roomtemperature for 40 min. The reaction mixture was passed through SiO₂column (diameter: 20 mm, height: 15 cm) saturated with NEt₃ (NEt₃ 1% inCH₂Cl₂:cyclohexane 1:2; 400 mL) using NEt₃ 1% in CH₂Cl₂:cyclohexane 1:2(125 mL) and then NEt₃ 1% in CH₂Cl₂:cyclohexane 1:1 100 mL to give 1(735 mg, 73%) as an oil: ¹H NMR (200 MHz, CDCl₃): δ=1.13-1.35 (m, 12H),1.51-2.06 (m, 16H), 2.66 (t, J=6.4 Hz, 2H), 3.11 (m, 2H), 3.32-3.98 (m,20H), 3.81 (s, 6H), 6.84 (m, 4H), 7.15-7.51 (m, 9H). ³¹P NMR (81 MHz,CDCl₃): 148.06, 148.13, 148.19, 148.3 (splitting due to amide rotationalisomerism).

EXAMPLE 2 Synthesis, Purification and Characterization of DecamerOligonucleotides Having Formula (Wherein CACCGTAGCG is SEQ ID NO:3)

Said oligonucleotides will be hereinafter designated by N₁₀S_(n) (N₁₀=anoligonucleotide moiety; S=a spermine residue and n=1-6).

Automated Synthesis:

A series of decamer oligonucleotides of identical sequencesN₁₀=^(3′)CACCGTAGCG^(5′) (SEQ ID NO:8) appended with increasing numbersof spermine residues S was synthetized using standard solid-phasecyanoethyl phosphoramidite chemistry on a Expedite DNA synthetizer,according to the following scheme:

the last N moiety being a nucleoside according to the classicaloligonucleotide synthesis.

Reagents used for automated DNA synthesis were purchased from GlenResearch (Eurogentec).

During the automated synthesis, the standard 1 μmol coupling cycle wasused, except for coupling of the spermine phosphoramidite 1 which wasdone with prolonged coupling time (15 min) and using a slightly moreconcentrated phosphoramidite solution (90 mg amidite in 1 mLacetonitrile).

Trityl fractions were collected, diluted and analyzed in aspectrophotometer to determine the stepwise coupling yields.

The coupling yields of the four natural nucleotides exceeded 97%, whilethe yields of the spermine phosphoramidite coupling were between 90 and96% in the above coupling conditions.

In all cases, the DMT-ON (ON=oligonucleotide) mode was used, keeping the5′-end DMT group uncleaved on oligomers for purification-identificationpurposes.

Post-Synthetic Treatment:

After automated synthesis, cleavage from the solid support and completedeprotection of oligomers were done using standard conditions (treatmentwith concentrated aqueous ammonia for 90 min at room temperature forcleavage and then overnight at 55° C. for deprotection).

Purification:

The first two anionic oligonucleotides N₁₀S₁ and N₁₀S₂ were initiallypurified in DMT-on state by standard HPLC procedure on a reverse-phasenucleosil C-18 column (Macherey-Nagel 10×250 mm) with a linear gradientof acetonitrile (5-35% in 20 min) in 20 mM ammonium acetate solution (pH7). Purified oligonucleotides were then detritylated by treatment withAcOH/H₂O=4/1 (500 mL) at r.t. for 20 min. After dilution with water (5mL), DMT-OH was eliminated by ether extraction (3×2 mL) and the aqueousphase was concentrated to afford the oligomers.

The HPLC analysis of oligonucleotides N₁₀S₁ and N₁₀S₂ is given in FIG. 1a reverse-phase nucleosil C-18 column (Macherey-Nagel 4.6×250 mm) with alinear gradient of acetonitrile (5-35% in 20 min) in 20 mM ammoniumacetate solution (pH 7): a) N₁₀S₁, crude, DMT-ON; b) N₁₀S₁, purified c)N₁₀S₂, crude, DMT-ON; d) N₁₀S₂, purified. *Benzamide; **Truncatedsequences.

The neutral oligomer N₁₀S₃ and the cationic oligomers N₁₀S₄, N₁₀S₅ andN₁₀S₆ (with or without DMT group) were purified using Poly-Pak II™ (GlenResearch/Eurogentec) columns according to the instruction given bymanufacturer except for the final oligonucleotide elution which was donewith acetonitrile/concentrated aqueous ammonia/water (20:4:80). Thefractions containing the oligonucleotide could be revealed using a TLCplate. After gathering the fractions, solvents were removed bylyophilization. The oligomers thus obtained were generally contaminatedby benzamide. It was eliminated by extraction with ether (three times)after dissolution in diluted aqueous ammonia solution (50 mM). Thepurified oligonucleotides were dissolved in diluted aqueous ammoniasolution (50 mM), and their concentration was determined using thefollowing extinction coefficient (260 nm, mol⁻¹ dm³ cm⁻¹):ε=(15.4N _(A)+11.5N _(G)+7.4N _(C)+8.7N _(T))×0.9×10³.

The HPLC analysis of purified oligonucleotides is given in FIG. 2: anionexchange column (Dionex PA-100 9×250 mm) with a linear gradient of NaCl(100-350 mM over 10 min)/NaOH 25 mM (pH 12.4): a) N₁₀S₁, b) N₁₀S₂, c)N₁₀S₃, d) N₁₀S₄, e) N₁₀S₅, f) N₁₀S₆.

Due to the conjugation chemistry employed, each polyamine comes with aphosphate group, hence contributing for a net additional cationiccharges. Seven oligonucleotides, (N₁₀S_(n))^(3n-9) n=0 . . . 6, withoverall charges −9, −6, −3, 0, +3, +6, +9 when fully ionized, where thusavailable in amounts ranging from 80 to 250 nanomoles.

Electrophoretic Mobility:

Their migration in an electric field at pH7 was studied bypolyacrylamide gel electrophoresis and revealed by silver mirrorstaining. Compounds (0.5 nmol) in 10 μL loading buffer (10 mM HEPES pH7.4, 150 mM NaCl, glycerol) were loaded onto a nondenaturatingpolyacrylamide gel (15% in TAE pH 7). Electrophoresis was run at 5 V/cmfor 17 h at 4° C. Silver staining was performed according to Rabilloudet al, Electrophoresis, 1987, 9, 288-291. The results are given in FIG.3. Oligonucleotide N₁₀ (lane 1) without spermine was moving fast towardsthe anode and showed only faint silver staining in conditions wherepolyamine-containing oligonucleotides were revealed.

Spontaneous Exchange of N₁₀ with N₁₀.C₁₀

Oligonucleotide C₁₀ (where C is the nucleotide complementary to N) (50pmol or 500 pmol) was added to the fluorescent N₁₀.C₁₀* duplex solution(50 pmol in HEPES 10 mM pH 7.4, NaCl 150 mM). The mixtures wereincubated 4 h at 37° C., 20° C. or 10° C. and loaded onto anondenaturing polyacrylamide gel (15% in TAE pH 7). Electrophoresis wasperformed at 4° C. for 17 h at 5 V/cm. C₁₀* fluorescence was detected byscanning the gel using a Typhoon 8600 Imager. As shown by the resultsgiven in FIG. 4, the spontaneous exchange of N₁₀ with N₁₀.C₁₀ is notsignificant at 10° C.

Strand Exchange Between N₁₀ and N₁₀S_(n)

The strand replacement capacity of N₁₀S_(n) towards the natural duplexN₁₀.C₁₀ was tested in physiological salt conditions.

Spermine conjugates N₁₀S_(n) (50 or 500 pmol) were added to afluorescent N₁₀.C₁₀* duplex solution (50 pmol in 10 mM HEPES pH 7.4, 150mM NaCl). The mixtures were incubated 4 h at 10° C. and loaded onto anondenaturing polyacryamide gel (15% in TAE pH 7). Electrophoresis wasperformed at 4° C. for 17 h at 5 V/cm. Fluorescence was detected byscanning the gel using a Typhoon 8600 Imager.

Spermine conjugation had a profound effect on the strand exchangereaction as shown in FIG. 5. The band corresponding to N₁₀.C₁₀ becameweaker as the number of spermine residues of the competing N₁₀S_(n)increased, in favour of a slower-moving, less anionic N₁₀S_(n).C₁₀complex. This effect was especially pronounced for N₁₀S₃, i.e., forconjugates which no longer bear a formal negative charge. Indeed,spermine is clipping duplex DNA structures by forming an interstrandnetwork of NH₂ ⁺ bidentate hydrogen bonds in the minor groove, hencewill favour N₁₀S_(n) binding over N₁₀. Yet an additional favourablekinetic factor may operate when strand exchange occurs in a preformed(N₁₀S_(n))^(3n-9)/(N₁₀C₁₀)¹⁸ electrostatic complex, which can be thecase for n>3.

Melting Temperatures of N₁₀S_(n).C₁₀ Duplexes

Stabilities of double stranded nucleic acids were compared by measuringtheir melting temperature, i.e. the temperature where complementarystrands cooperatively fall apart. Optical density (O.D.) was thereofrecorded at 260 nm of solutions of N₁₀S_(n).C₁₀ vs. temperature T.

Melting temperatures T_(m) were measured in HEPES 10 mM pH 7.4 (blackline, rhombi) and in HEPES 10 mM pH 7.4+150 mM NaCl (grey line,circles). Melting profiles of all duplexes (3.75 nmol in 1 ml buffer)were obtained using a CARY 4000 Spectrophotometer equipped with atemperature control unit by gradually heating the samples (1° C./min)while recording their absorbance at 260 nm. Duplex melting results in ahyperchromic shift and T_(m) is the temperature where the firstderivative curve dO.D./dT=f(T) reaches its maximum. The results aregiven in FIG. 5.

The natural duplex melted at T_(m)=30° C. in 10 mM HEPES pH 7.4 (FIG.5). Conjugation of increasing numbers of spermines led to remarkableT_(m) increases. N₁₀S₆—C₁₀ melted at T_(m)=75.2° C., some 45° C. higherthan the natural duplex. The T_(m)=f(n) curve showed a sigmoidal shapewith an inflection for the neutral N₁₀S₃ oligonucleotide.

Melting temperatures were also recorded in physiological saltconditions. The T_(m)=f(n) curve appeared much clamped and, remarkably,crossed the previous curve for N₁₀S₃. Thus for n<3, both N₁₀S_(n) andC₁₀ oligonucleotides are anionic and repel each other in the duplex;increasing the solution salt concentration shields repulsive forceshence increases T_(m). For n>3 N₁₀S_(n) becomes cationic and attractsC₁₀; here salt-induced electrostatic shielding decreases stability.

For the neutral N₁₀S₃, duplex stability is independent of saltconcentration.

Comparison of Melting Temperatures of Duplexes Formed by N.sub.10S.sub.n(n=0-6) with ^(5′) GTGGCATCGC^(3′) (SEQ ID NO:1) and with^(5′)GTGGCGTCGC^(3′) SEQ ID NO:2)

A single base pair mismatch discrimination of theoligonucleotide-spermine conjugates was tested. Within the sequencecontext of C₁₀=^(5′)GTGGCATCGC^(3′) (SEQ ID NO:1), literature datarecommended a centrally-located A-to-G conversion as being the moststringent test.

Melting temperatures T_(m) were measured in HEPES 10 mM pH 7.4+NaCl 150mM. Melting profiles of all duplexes (3.75 nmol in 1 mL buffer) wereobtained using a CARY 4000 Spectrophotometer equipped with a temperaturecontrol unit by gradually heating the samples (1° C./min) whilerecording their absorbance at 260 nm. T_(m) is the temperature where thefirst derivative curve dO.D./dT=f(T) reaches its maximum. The resultsare given on FIG. 7 (rhombi correspond to ^(5′)GTGGCATCGC^(3′) (SEQ IDNO:1) and triangles to ^(═′)GTGGCGTCGC^(3′) (SEQ ID NO:2)).

The transition temperature of the natural N₁₀.C₁₀ duplex in 150 mM NaClfell from 50.6° C. to 42.9° C., i.e. DT_(m)=7.7° C. when the mismatchwas present. In principle, stability increase due to nonspecific,end-conjugated electrostatic forces should not impair base pairspecificity, which is expressed as ΔΔG. This is indeed what wasobserved, as the complementary and mismatch target oligonucleotideshowed quasi-parallel T_(m)=f(n) curves with average ΔT_(m)=7.9° C.

ES-MS Analysis of Purified N₁₀S_(n) Oligonucleotides.

Oligonucleotides were dissolved in 50% aqueous acetonitrile (v/v)containing 1% triethylamine at a final concentration of 5×10⁻⁵ M. 100 mLaliquots were introduced into the ion source of an Applied BiosystemsMariner 5155 mass spectrometer at a flow rate of 5 mL/min. The resultsare given in FIG. 8 (insets: deconvoluted spectra): a) N₁₀S₁, b) N₁₀S₂,c) N₁₀S₃, d) N₁₀S₄, e) N₁₀S₅, f) N₁₀S₆. Ionization of the neutral andcationic oligomers N₁₀S₃ became more difficult and it was necessary toaccumulate several spectra to obtain acceptable signal-to noise ratio.

EXAMPLE 3 Synthesis, Purification and Characterization of 12-MerThiophosphate Oligonucleotides Having Formula (Wherein GCGACTCATGAA isSEQ ID NO:4)

Said oligonucleotides will be thereafter designated by N₁₂S_(n)F (N=a12-mer oligonucleotide thiophosphate moiety; S=a spermine residue andn=2 or 11; F=fluorescein conjugated to thymine).

Automated Synthesis:

Twelve-mer thiophosphate oligonucleotides of sequenceN₁₂=³GCGACTCATGAA^(5′) (SEQ ID NO:4) appended with two or 11 spermineresidues S were synthetized using solid-phase cyanoethyl phosphoramiditechemistry on an Expedite DNA synthetizer. Ultramild CE phosphoramiditesand ultramild supports (Glen Research/Eurogentec) were used in order toavoid oligomer cleavage during work-up. A standard sulfurizing reagent(Glen Research/Eurogentec) was used to generate the phosphorothioatelinkages in the 12-mer oligonucleotide moiety. Fluorescein-dTphosphoramidite (Glen Research/Eurogentec) was used for 5′-endlabelling. Spermine phosphoramidite coupling was performed using thecoupling protocol described in example 2.

Trityl fractions were collected, diluted and analyzed in aspectrophotometer to determine the stepwise coupling yields.

In all cases, the DMT-ON mode was used, keeping the 5′-end DMT groupuncleaved on oligomers for purification-identification purposes.

Post-Synthetic Treatment:

After automated synthesis, cleavage from the solid support and completedeprotection of oligomers were performed by treatment with concentratedaqueous ammonia overnight at room temperature.

Purification:

DMT-ON compounds N₁₂S₂F and N₁₂S₁F were purified using Poly-Pak II™columns (Glen Research/Eurogentec) according to instructions given bythe manufacturer.

Purified oligonucleotides N₁₂S_(n)F (n=2, 11) were analyzed on an anionexchange column (SAX1000-8) in aqueous basic conditions (100 mM ammonia,pH 11) using a NaCl gradient (0.75-2.5 M in 20 min). HPLC traces areshown in FIG. 9 (A: N₁₂S₁₁F, B: N₁₂S₂F).

MALDI-TOF MS Analysis of Purified Oligonucleotides.

Oligonucleotides were dissolved in 500 μL of deionized water. The sampleand HPA matrix were mixed together on the plate. Once crystallized, thesample was analyzed with a BRUKER Ultraflex MS apparatus. Results aregiven in FIG. 10 A: N₁₂S₂F calc 5460. found 5459 (upper) and FIG. 10 B:N₁₂S₁₁F calc: 9135 found 9125 (lower).

EXAMPLE 4 Plasmid DNA Strand Invasion with 14-Mer and 20-Mer FluorescentOligonucleotides (Wherein TCGCCAAGGTAGAA is SEQ ID NO:5)

Compounds shown above will be thereafter designated by N₁₄S_(n)F (N=anoligonucleotide moiety; S=a spermine residue with n=24; F=a fluoresceinresidue) and by N₂₀S_(n)F (N=an oligonucleotide moiety; S=a spermineresidue with n=3-5; F=a fluorescein residue).

These fluorescent oligonucleotides were synthesized following theprocedure described in example 2. 5′-Fluorescein phosphoramidite (GlenResearch/Eurogentec) was used for 5′-end labelling. Analytical HPLCtraces and MALDI-TOF MS spectra for the most substituted N₁₄S₄F andN₂₀S₅F compounds are shown in FIGS. 11 and 12 as proofs of purity andstructure (N₁₄S₄F calc 6470. found 6478; N₂₀S₅F calc 8813 found 8815),respectively.

Oligonucleotide sequences of N₁₄S_(n)F and N₂₀S_(n)F were chosen withinthe Luciferase gene sequence of the pGL3 control plasmid (Promega). Toassess the sequence specificity of strand invasion, pGL2 control plasmid(Promega) was used. The GL2 Luciferase sequence is 95% identical to GL3,and the sequences targeted by N₁₄S_(n)F and N₂₀S_(n)F containrespectively one and two mismatches.

The ability of N₁₄S_(n)F and N₂₀S_(n)F to strand-invade pGL3 and notpGL2 plasmids was tested in physiological salt and temperatureconditions.

Fluorescent conjugates N₁₄S_(n)F and N₂₀S_(n)F (8.65 pmol) were added toa solution of plasmid (1.5 μg, 0.43 pmol in 10 mM HEPES pH 7.4, 150 mMNaCl). The mixtures were incubated 24 h at 37° C. and loaded onto anagarose gel (1.3% in TAE pH 7.4). Electrophoresis was performed at roomtemperature for 45 min after what fluorescein green emission wasdetected by scanning the gel using a Typhoon 8600 Imager. A redfluorescence picture of the gel was taken on an UV transilluminatorfollowing a 15 min incubation in ethidium bromide solution. The resultsare given in FIG. 13.

Red and green fluorescences are evidence of double stranded plasmid DNAand fluorescent oligonucleotide, respectively. Their colocalization withpGL3 and not with pGL2 is thus evidence for strand invasion. CompoundsN₁₄S₃F and N₂₀S_(n)F showed a faint green fluorescent band associatedwith the plasmid when incubated with pGL3 and not with pGL2.

EXAMPLE 5 Penetration of Cationic Oligonucleotides into Cells

Hela cells, grown in 10% (v/v) fetal calf serum containing MEM medium,were plated at 50-60×10³ cells/well into 4-well chambered borosilicateLab-Tek dishes one day prior to the experiment. Complete medium wasreplaced by 0.5 ml serum-free MEM medium. A 5′-cationicfluorescein-conjugated oligonucleotide F—S₁₈N₁₉ (where N₁₉ isTCGAAGTACTCAGCGTAAG (SEQ ID NO:7)) formulation was prepared in sterilePBS. It was added to the cells to a final concentration of 2 μM. Fourhours later, the medium was replaced by 1 ml of fresh serum-containingmedium. A first picture was taken with a Zeiss axiovert 25 fluorescencemicroscope, equipped with a FITC filter (FIG. 14 A, left). All cellsbecame fluorescent, with some fluorescence located in intracellularvacuoles and, most importantly, also spread throughout the cytoplasm andnucleus. After 24 h, the medium was replaced with 1 ml of phenolred-free MEM medium. Propidium iodide (1 mM in water) was added to afinal concentration of 10 .mu.M. Ten minutes later, a second picture wastaken showing a majority of propidiumless healthy cells that were stillfluorescent (FIG. 14 B, right). The control cells that were incubated insimilar conditions with F—N19 oligonucleotide showed no fluorescence.

The invention thus provides a versatile automatic synthesis of cationicoligonucleotides that form fast and stable complexes with theircomplementary sequence even in a strand invasion context. Due to endconjugation, sequence selectivity remains as high as for naturaloligonucleotides. Moreover, thanks to their cationic nature,intracellular delivery does not require complex formation with cationiccarrier molecules. Taken together, these properties makeoligonucleotide-oligocation conjugates attractive alternatives tooligonucleotides for molecular biology, diagnostics as well astherapeutic applications.

The invention claimed is:
 1. Oligonucleotide-oligocation molecules ABHthat can be synthetized via automated phosphoramidite chemistry havingoligonucleotides moieties Ai and oligocations moieties Bj, wherein A_(i)is an i-mer oligonucleotide residue, with i=5 to 50, with naturally ornon naturally occurring nucleobases and/or pentafuranosyl groups and/ornative phosphodiester bonds, as well as their chemical modifications orsubstitutions, Bj is a j-mer organic oligocation repeated B block, withj=2 to 50, where B is selected from the group comprising HPO₃—R¹—(X—R²_(n))_(n1)—X—R³—O—, where R¹, R² _(n) and R³, identical or different,are lower alkylene, X is NH or NC(NH₂)₂, n varies from 1 to 5 and n1=2to 20, HPO₃—R⁴—CH(R⁵X¹)—R⁶—O—, where R⁴ is lower alkylene, R⁵ and R⁶,identical or different, are lower alkylene and X¹ is putrescine,spermidine or spermine, and HPO₃—R⁷-(aa)_(n2)-R⁸—O—, where R⁷ is loweralkylene and R⁸ is lower alkylene, serine, a natural amino alcohol,(aa)_(n2) is a peptide containing natural amino acids with cationic sidechains, and n2=2 to 20, wherein B groups are oligomerized by a stepwisesynthesis through a phosphodiester linkage to form B_(j) and whereinA_(i) is linked to B_(j) through a phosphodiester linkage.
 2. Themolecules of claim 1, wherein the A_(i) oligonucleotide is selected fromthe group comprising deoxyribo, ribo, locked (LNA) nucleotides as wellas their chemical modifications or substitutions.
 3. The molecules ofclaim 2, wherein the modifications or substitutions arephosphorothioate, 2′-fluoro, or 2′-O-alkyl.
 4. The molecules of claim 1,wherein the A_(i) oligonucleotide is substituted by a marker which is afluorescent agent.
 5. The molecules according to claim 1 wherein theamino acids are Arginine, Lysine, Ornithine, Histidine, Diaminopropionicacid.
 6. The molecules of claim 1, having a ^(3′)A^(5′)-B sequence. 7.The molecules of claim 1, having a B-^(3′)A^(5′)-sequence.
 8. Themolecules of claim 1, having B-^(3′)A^(5′)-B or^(3′)A^(5′)-B-^(3′)A^(5′) sequences as well as their combinations.
 9. Amethod for obtaining oligonucleotide-oligocation molecules according toclaim 1, by using a stepwise synthesis on an oligonucleotidesynthetizer, via a phosphoramidite route, comprising plugging vialscontaining activated and protected oligocations B into anoligonucleotide synthetizer, in addition to vials of oligonucleotides A,or plugging vials of oligonucleotide A into an oligonucleotidesynthesizer, in addition to vials containing activated and protectedoligocations B, stopping synthesis when a desired oligomer length isobtained, cleaving oligomers from a solid support, and removingprotecting groups.
 10. The method of claim 9, wherein thephosphoramidite reagents are selected from the group comprising:P(OR⁹)(N(R¹⁰)₂)—O—R¹—(X—R²)_(n1)—X—R³—O-Prot, where R¹, R², R³, and n1R¹, R² _(n) and R³, identical or different are lower alkylene and n1=2to 20, X is suitably protected NH or NC(NH₂)₂, R⁹ is —CH₂CH₂CN, or loweralkyl, R¹⁰ is lower alkyl, or —N(R¹⁰)₂ is pyrrolidino, piperidino ormorpholino group, and Prot is a protecting group used in oligonucleotidesynthesis such as DMT, MMT; P(OR⁹)(N(R¹⁰)₂)—O—R⁴—CH(R⁵X1)-R⁶—O-Prot,where R⁴, R⁵, R⁶ are lower alkylene, X¹ is suitably protectedputrescine, spermidine or spermine, R⁹ is CH₂CH₂CN or lower alkyl, R¹⁰is a lower alkyl, or —N(R¹⁰)₂ is pyrrolidino, piperidino or morpholinogroup; P(OR⁹)(N(R¹⁰)₂)—O—R⁷-(aa)_(n2)-R⁸—O-Prot, wherein R⁷ is loweralkylene and R⁸ is lower alkylene, R⁹ is CH₂CH₂CN or lower alkyl, R¹⁰ isa lower alkyl, or —N(R¹⁰)₂ is pyrrolidino, piperidino or morpholinogroup, n2=2 to 20, (aa)_(n2) is a peptide containing natural amino acidswith cationic side chains and Prot is a protecting group used inoligonucleotide synthesis such as DMT or MMT.
 11. The method of claim 9,wherein stepwise synthesis of a oligonucleotide sequence is followed bya stepwise synthesis of a oligocation moiety to obtain compounds havingsequence (^(3′)A^(5′)-B).
 12. The method of claim 9, wherein a stepwisesynthesis of a oligocation moiety is followed by stepwise synthesis of aoligonucleotide sequence to obtain compounds of (B-^(3′)A^(5′))sequence.
 13. The method of claim 9, comprising a synthesis of mixedsequences.
 14. The method of claim 13, comprising a synthesis ofoligonucleotide sequences capped at both ends (B-^(3′)A^(5′)-B) oroligonucleotide sequences cation-interrupted sequences(^(3′)A^(5′)-B-^(3′)A^(5′)).
 15. The method of claim 9, wherein theactivated and protected oligocations B are obtained by protecting theamino groups of a polyamine, followed by α,ω-bis hydroxylalkylation andobtaining diols compatible with oligonucleotide synthesis. 16.Pharmaceutical compositions comprising an effective amount ofoligonucleotide-oligocation molecules according to claim 1, inassociation with a pharmaceutically acceptable carrier. 17.Oligonucleotide-oligocation molecules AiBjH that can be synthesized viaautomated phosphoramite chemistry having oligonucleotides moieties A_(i)and oligocations moieties B_(j) wherein A_(i) is an i-meroligonucleotide residue, with i=5 to 50 and is a phosphorothioateoligonucleotide, Bj is a j-mer organic oligocation repeated B block,with j=2 to 50, where B is selected from the group comprising:HPO₃—R¹—(X—R² _(n))_(n1)—X—R³—O—, where R¹, R² _(n) and R³, identical ordifferent are lower alkylene, X is NH or NC(NH₂)₂ n varies from 1 to 5and n1=2 to 20, HPO₃—R⁴—CH(R⁵X¹)—R⁶—O—, where R⁴ is lower alkylene, R⁵and R⁶, identical or different, are lower alkylene and X¹ is putrescine,spermidine or spermine residue, and —HPO₃—R⁷-(aa)_(n2)-R⁸—O—, where R⁷is lower alkylene and R⁸ is lower alkylene, serine, a natural aminoalcohol, (aa)_(n2) is a peptide containing natural amino acids withcationic side chains and n2=2 to 20, wherein B groups are oligomerizedby a stepwise synthesis through a phosphodiester linkage to form B_(j)and wherein A_(i) is linked to B_(j) through a phosphodiester linkage.18. Oligonucleotide-oligocation molecules AiBjH that can be synthesizedvia automated phosphoramite chemistry consisting of oligonucleotidesmoieties A_(i) and oligocations moieties B_(j) wherein A_(i) is an i-meroligonucleotide residue, with i=5 to 50, with naturally or non naturallyoccurring nucleobases and/or pentafuranosyl groups and/or nativephosphodiester bonds, as well as their chemical modifications orsubstitutions, Bj is a j-mer organic oligocation repeated B block, withj=2 to 50, where B is selected from the group comprising HPO₃—R¹—(X—R²_(n))_(n1)—X—R³—O—, where R¹, R² _(n) and R³, identical or different arelower alkylene, X is NH or NC(NH₂)₂ n varies from 1 to 5 and n1=2 to 20,HPO₃—R⁴—CH(R⁵X¹)—R⁶—O—, where R⁴ is lower alkylene, R⁵ and R⁶, identicalor different, are lower alkylene and X¹ is putrescine, spermidine orspermine residue, and —HPO₃—R⁷-(aa)_(n2)-R⁸—O—, where R⁷ is loweralkylene and R⁸ is lower alkylene, serine, a natural amino alcohol,(aa)_(n2) is a peptide containing natural amino acids with cationic sidechains and n2=2 to 20, wherein B groups are oligomerized by a stepwisesynthesis through a phosphodiester linkage to form B_(j) and whereinA_(i) is linked to B_(j) through a phosphodiester linkage.